Salesforce Stock Just Soared. Thank Anthropic.

Salesforce reported fiscal Q2 2027 adjusted EPS of $5.90 (up 103% YoY), but $2.53 of that was gains on strategic investments—primarily $2.7B unrealized gains tied to its Anthropic stake. Excluding investment gains, adjusted EPS grew ~16% YoY to about $3.37, while revenue rose 11% to $11.3B and operating cash flow jumped 71% to $1.3B. Salesforce also raised its full-year revenue outlook to $46.1B–$46.4B (11%–12% growth) and launched/expanded Claudeforce with Anthropic, contributing to shares soaring nearly 23%.

Analysis

This print re-rates CRM less as a pure software compounder and more as a hybrid operating company plus embedded venture book. That matters because the market is likely to over-assign earnings quality to a mark-to-market asset that can swing sharply, while under-assigning the strategic value of letting CRM own the workflow layer inside a leading model ecosystem. The second-order winner is enterprise AI adoption itself: if Claude becomes a default interface for sales ops, the incremental value pool shifts toward system-of-record vendors with data gravity, not standalone copilots.

Near term, the stock can keep working because per-share optics are being supported by buybacks and a still-constructive AI narrative, but the next catalyst is organic conversion: does the AI bucket turn into durable subscription expansion and better retention, or does it remain a label on ARR? The main tail risk is an Anthropic valuation reset or markdown, which would hit reported EPS instantly and could reverse sentiment even if core software stays fine. That makes the next 1-3 months a catalyst trade, while the 6-18 month view depends on whether AI features actually widen CRM's moat versus MSFT, NOW, and ADBE.

Contrarian view: the market may be underestimating how much of the move is financial engineering and overestimating how much is true operating acceleration. Ex-gain growth is respectable, not exceptional, so a premium multiple needs proof that AI is expanding wallet share rather than just defending the franchise. The post-gap move looks partially extended; better entries likely come on pullbacks or through defined-risk structures instead of chasing common stock after a one-day repricing.

Key Decisions for Investors

• Buy CRM only on a pullback into the low-$240s, targeting a 1-3 month re-test of the post-earnings high; use a stop back below the gap zone because that would signal the market is rejecting the quality of earnings story.
• For a cleaner expression of enterprise-AI upside, pair long CRM vs short ADBE over the next 1-3 months; CRM has better distribution leverage from model integration, while ADBE faces higher risk of AI-driven feature commoditization.
• If already long CRM, finance it with covered calls into the post-earnings volatility; the one-off investment gain makes near-term upside less linear than the chart implies.
• Watch for a markdown or valuation pause in Anthropic on the next private funding headlines; that is the key falsifier for the reported EPS boost and would likely compress CRM's multiple quickly.